Steven Mah
Stock Analyst at TD Cowen
(2.03)
# 2,741
Out of 4,829 analysts
31
Total ratings
31.03%
Success rate
7.66%
Average return
Main Sectors:
Stocks Rated by Steven Mah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Reiterates: Buy | $58 | $30.82 | +88.19% | 3 | Nov 26, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $28 → $31 | $23.29 | +33.10% | 2 | Nov 13, 2024 | |
| DNA Ginkgo Bioworks Holdings | Maintains: Outperform | $280 → $120 | $7.76 | +1,446.39% | 2 | Mar 1, 2024 | |
| RXRX Recursion Pharmaceuticals | Initiates: Market Perform | n/a | $4.33 | - | 1 | Jan 26, 2024 | |
| SDGR Schrödinger | Initiates: Outperform | $42 | $23.91 | +75.66% | 1 | Jan 26, 2024 | |
| ABCL AbCellera Biologics | Initiates: Outperform | n/a | $2.03 | - | 1 | Feb 28, 2023 | |
| OABI OmniAb | Initiates: Outperform | $10 | $1.44 | +594.44% | 1 | Feb 22, 2023 | |
| ABSI Absci | Upgrades: Outperform | n/a | $2.75 | - | 1 | Aug 12, 2022 | |
| CDXS Codexis | Maintains: Outperform | $39 → $21 | $2.46 | +753.66% | 2 | Jul 15, 2022 | |
| NTRA Natera | Maintains: Overweight | $150 → $155 | $151.95 | +2.01% | 4 | Jul 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $1.10 | +2,445.45% | 1 | May 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $19.70 | +610.66% | 3 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $20 → $52 | $1.12 | +4,542.86% | 3 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $340 → $415 | $75.76 | +447.78% | 4 | Dec 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $80 | $2.87 | +2,687.46% | 1 | Dec 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $168 → $250 | $36.36 | +587.57% | 1 | Jul 8, 2020 |
Twist Bioscience
Nov 26, 2024
Reiterates: Buy
Price Target: $58
Current: $30.82
Upside: +88.19%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $28 → $31
Current: $23.29
Upside: +33.10%
Ginkgo Bioworks Holdings
Mar 1, 2024
Maintains: Outperform
Price Target: $280 → $120
Current: $7.76
Upside: +1,446.39%
Recursion Pharmaceuticals
Jan 26, 2024
Initiates: Market Perform
Price Target: n/a
Current: $4.33
Upside: -
Schrödinger
Jan 26, 2024
Initiates: Outperform
Price Target: $42
Current: $23.91
Upside: +75.66%
AbCellera Biologics
Feb 28, 2023
Initiates: Outperform
Price Target: n/a
Current: $2.03
Upside: -
OmniAb
Feb 22, 2023
Initiates: Outperform
Price Target: $10
Current: $1.44
Upside: +594.44%
Absci
Aug 12, 2022
Upgrades: Outperform
Price Target: n/a
Current: $2.75
Upside: -
Codexis
Jul 15, 2022
Maintains: Outperform
Price Target: $39 → $21
Current: $2.46
Upside: +753.66%
Natera
Jul 6, 2021
Maintains: Overweight
Price Target: $150 → $155
Current: $151.95
Upside: +2.01%
May 11, 2021
Initiates: Overweight
Price Target: $28
Current: $1.10
Upside: +2,445.45%
Mar 5, 2021
Maintains: Overweight
Price Target: $135 → $140
Current: $19.70
Upside: +610.66%
Feb 11, 2021
Upgrades: Overweight
Price Target: $20 → $52
Current: $1.12
Upside: +4,542.86%
Dec 22, 2020
Upgrades: Overweight
Price Target: $340 → $415
Current: $75.76
Upside: +447.78%
Dec 16, 2020
Upgrades: Overweight
Price Target: $40 → $80
Current: $2.87
Upside: +2,687.46%
Jul 8, 2020
Maintains: Overweight
Price Target: $168 → $250
Current: $36.36
Upside: +587.57%